Stålhammar Gustav, See Thonnie Rose, Filì Maria, Seregard Stefan
St. Erik Eye Hospital, Stockholm, Sweden.
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Ocul Oncol Pathol. 2019 Oct;5(6):432-439. doi: 10.1159/000497186. Epub 2019 Mar 19.
In several malignancies, gender-based survival differences after specific therapeutic interventions have been demonstrated. It is not known whether such differences exist after plaque brachytherapy of uveal melanoma.
All patients who received brachytherapy for uveal melanoma at St. Erik Eye Hospital from November 1, 1979 through November 20, 2017 were included ( = 1,541). Retrospective data were retrieved including baseline patient and tumor characteristics, brachytherapy nuclide (ruthenium-106 or iodine-125), radiation dose, treatment duration, tumor relapses, date of metastasis, and cause of death.
A total of 775 men and 766 women were treated with plaque brachytherapy. There were no significant differences between the genders in baseline characteristics, treatment, or follow-up. Men and women had similar rates of tumor relapses, hazard for repeated brachytherapy (men vs. women 0.8, = 0.47), enucleation-free survival, and survival after detection of metastasis. Five-, 10-, and 15-year melanoma-related mortality was 14, 24, and 27% for men and 15, 26, and 32% for women, respectively. There were no significant differences in hazard for melanoma-related mortality (men vs. women 0.9, = 0.32), median Kaplan-Meier disease-specific survival (men 18.2 years, women 15.5 years, = 0.22), or median overall survival (men 13.5 years, women 12.6 years, = 0.60).
There are no relevant differences between men and women in ocular or patient survival after brachytherapy for uveal melanoma.
在几种恶性肿瘤中，特定治疗干预后的生存存在性别差异。目前尚不清楚葡萄膜黑色素瘤进行斑块近距离放射治疗后是否存在此类差异。
纳入1979年11月1日至2017年11月20日在圣埃里克眼科医院接受葡萄膜黑色素瘤近距离放射治疗的所有患者（n = 1541）。检索回顾性数据，包括患者和肿瘤的基线特征、近距离放射治疗核素（钌-106或碘-125）、辐射剂量、治疗持续时间、肿瘤复发、转移日期和死亡原因。
共有775名男性和766名女性接受了斑块近距离放射治疗。男女在基线特征、治疗或随访方面无显著差异。男性和女性的肿瘤复发率、再次进行近距离放射治疗的风险（男性对女性0.8，P = 0.47）、无眼球摘除生存率以及转移检测后的生存率相似。男性的5年、10年和15年黑色素瘤相关死亡率分别为14%、24%和27%，女性分别为15%、26%和32%。黑色素瘤相关死亡风险（男性对女性0.9，P = 0.32）、Kaplan-Meier疾病特异性生存中位数（男性18.2年，女性15.5年，P = 0.22）或总生存中位数（男性13.5年，女性12.6年，P = 0.60）均无显著差异。
葡萄膜黑色素瘤近距离放射治疗后，男女在眼部或患者生存方面无相关差异。
